Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 14/20 | 0.56 |
| ▸ | PPARG | P37231 | 12/20 | 0.56 |
| ▸ | PPARD | Q03181 | 3/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6359747 | 1.00 | PPARA (0.56) | PPARAPPARGPPARDCA12CA1 | |
| SCHEMBL6359783 | 1.00 | PPARA (0.56) | PPARAPPARGPPARDCA12CA1 | |
| SCHEMBL6362301 | 0.92 | PPARA (0.64) | PPARAPPARGPPARDCA12CA1 | |
| SCHEMBL6359007 | 0.91 | PPARA (0.61) | PPARAPPARGPPARDCA12CA1 | |
| SCHEMBL6364127 | 0.91 | PPARA (0.58) | PPARAPPARGPPARDCA12CA1 | |
| SCHEMBL6361165 | 0.91 | PPARA (0.61) | PPARAPPARGPPARDCA12CA1 | |
| SCHEMBL6361171 | 0.91 | PPARA (0.61) | PPARAPPARGPPARDCA12CA1 | |
| SCHEMBL6363401 | 0.91 | PPARA (0.58) | PPARAPPARGPPARDCA12CA1 | |
| SCHEMBL6363531 | 0.91 | PPARA (0.61) | PPARAPPARGPPARDCA12CA1 | |
| SCHEMBL6364111 | 0.90 | PPARA (0.60) | PPARAPPARGPPARDCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2004520397-A | — | — | 2004-07-08 | — | — | JP | claimed |
| EP-1372632-A1 | PROLIFERATIVE ACTIVATOR RECEPTOR (PPAR) COMPOUNDS | Pfizer Products Inc. (US) | 2004-01-02 | — | — | EP | claimed |
| US-20020169192-A1 | PPAR compounds | HAYWARD CHERYL M (US) | 2002-11-14 | — | — | US | claimed |
| WO-2002064130-A1 | PROLIFERATIVE ACTIVATOR RECEPTOR (PPAR) COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2002-08-22 | — | — | WO | claimed |
| US-20050075377-A1 | PPAR compounds | PFIZER INC | 2005-04-07 | — | — | US | disclosed |
| US-6852161-B2 | METHOD OF FABRICATING GROUP-III NITRIDE SEMICONDUCTOR CRYSTAL, METHOD OF FABRICATING GALLIUM NITRIDE-BASED COMPOUND SEMICONDUCTOR, GALLIUM NITRIDE-BASED COMPOUND SEMICONDUCTOR, GALLIUM NITRIDE-BASED COMPOUND SEMICONDUCTOR LIGHT-EMITTING DEVICE, AND LIGHT SOURCE USING THE SEMICONDUCTOR LIGHT-EMITTING DEVICE | SHOWA DENKO K.K. (JP) | 2005-02-08 | — | — | US | disclosed |
| EP-1372632-A1 | PROLIFERATIVE ACTIVATOR RECEPTOR (PPAR) COMPOUNDS | Pfizer Products Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20020169192-A1 | PPAR compounds | HAYWARD CHERYL M (US) | 2002-11-14 | — | — | US | disclosed |
| US-20020155712-A1 | Method of fabricating group-III nitride semiconductor crystal, method of fabricating gallium nitride-based compound semiconductor, gallium nitride-based compound semiconductor, gallium nitride-based compound semiconductor light-emitting device, and light source using the semiconductor light-emitting device | TOYODA GOSEI CO., LTD. (JP) | 2002-10-24 | — | — | US | disclosed |
| WO-2002064130-A1 | PROLIFERATIVE ACTIVATOR RECEPTOR (PPAR) COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002017369-A1 | METHOD OF FABRICATING GROUP-III NITRIDE SEMICONDUCTOR CRYSTAL, METHO OF FABRICATING GALLIUM NITRIDE-BASED COMPOUND SEMICONDUCTOR, GALLIUM NITRIDE-BASED COMPOUND SEMICONDUCTOR, GALLIUM NITRIDE-BASED COMPOUND SEMICONDUCTOR LIGHT-EMITTING DEVICE, AND LIGHT SOURCE USING THE SEMICONDUCTOR LIGHT-EMITTING DEVICE | SHOWA DENKO K.K. (JP) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169192-A1 | PPAR compounds | PPARA, PPARG, PPARD | PPARA 1/4885PPARG 2/4885PPARD 3/4885 |
| US-20050075377-A1 | PPAR compounds | PPARA, PPARG, PPARD | PPARA 1/4885PPARG 2/4885PPARD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.